This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys

Findell Capital initiated a new third‑quarter position in Mineralys Therapeutics, acquiring 250,000 shares valued at $9.5 million (3.7% of its $253.4 million U.S. equity portfolio) according to a Nov. 14 SEC filing; the fund holds 15 positions. Mineralys shares closed at $43.36 (up ~246% over the past year), with a market cap of ~$3.4 billion; the clinical‑stage company reported no product revenue, a Q3 net loss of $36.9 million and a TTM net loss of $171.4 million, and recently upsized an offering to raise $287.5 million to extend its cash runway while advancing lorundrostat for resistant hypertension.

Analysis

Market structure: Findell’s $9.5M initiation accentuates institutional demand for MLYS and tightens float-driven liquidity; winners are early institutional holders, CROs and CDMOs involved in lorundrostat, while generic hypertension incumbents face only theoretical long-term pressure if efficacy + outcomes materialize. The Sept upsized $287.5M raise materially extends runway and reduces near-term supply of new equity, which combined with 246% YTD performance suggests momentum-driven flows will remain a primary price driver over the next 1–3 months.

Risk assessment: The dominant tail risks are binary clinical failure or safety signal (Phase 2/3 readout) and a subsequent forced dilution if cash burn (~$35–45M/q implied by Q3 loss) outpaces revenues — the raise implies ~12–18 months runway at current burn rates. Immediate (days) risk is a momentum pullback; short-term (weeks–months) hinge on enrollment and data cadence; long-term (1–3 years) depends on CV outcomes, payer acceptance and competitive ASI entrants.

Trade implications: For investors wanting asymmetric exposure, prefer defined-risk option structures over naked equity: buy 9–15 month call spreads (e.g., buy $45 / sell $80) sized to 1–2% of NAV to capture positive readouts while capping downside. For income-oriented or tactical traders, consider selling 30–60 day calls after >15% price pops to harvest elevated IV, and pair long MLYS (1%) with a 0.5–1% hedge in large-cap healthcare (JNJ or MRK) to reduce idiosyncratic binary risk.

Contrarian angles: The market may be over-rewarding funding and momentum versus de-risked clinical proof — the capital raise reduces immediate dilution risk but does not change binary efficacy odds; historical parallels include small-cap biotech runs that retraced >50% after trial misses. Monitor short interest (>10%), upcoming protocol amendments, and any FDA Type A/B meetings as >30-day catalysts that could flip sentiment rapidly.

Key Decisions for Investors

• Establish a defined-risk long sized 1–2% of portfolio in MLYS via a 9–15 month call spread (example: buy 12-month $45 call, sell $80 call) to limit capital at risk while retaining upside to clinical/catalyst events.
• If preferring straight equity, only buy on a conviction pullback: initiate up to 1% position if MLYS falls >15% from current $43.36, use a 30% stop-loss, and scale out at +100% and +200% gains.
• Tactically sell short-dated (30–60 day) calls after any >15% intraday pop to capture elevated IV; size to no more than 0.5% of NAV and avoid naked exposure around known data/event windows.
• Reduce small-cap biotech beta by 200 basis points and reallocate that risk into 200 bps in large-cap defensive healthcare (examples: JNJ, MRK) to hedge sector concentration while MLYS remains binary; reassess after the next 6–12 month clinical milestones.
• Monitor three concrete triggers over the next 6–18 months before increasing exposure: (1) confirmed cash runway ≥12 months in the next 10-Q, (2) positive interim BP or safety signals from lorundrostat (pre-specified endpoints), (3) any FDA meeting outcome — add to 3–4% position only after 2/3 triggers are met.